智通财经APP讯,常山药业(300255.SZ)公告,公司与控股子公司常山凯捷健生物药物研发(河北)有限公司于近日收到国家药品监督管理局下发的创新药艾本那肽临床试验申请《受理通知书》,申请的适应症为:拟用于肥胖(BMI≥28kg/m²),超重(BMI>24且。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.